AVI BioPharma to Present Data on RNA-Based Duchenne Muscular Dystrophy and Influenza Drug Candidates at 6th Annual Meeting of th
October 20 2010 - 8:30AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced the presentation of data from the
Company's Duchenne muscular dystrophy and influenza programs at the
6th Annual Meeting of the Oligonucleotide Therapeutics Society in
Dana Point, Calif.
Peter Sazani, Executive Director, Preclinical Development at
AVI, will present during the poster session at noon PDT on Friday,
Oct. 22. The presentation, 063, is titled "Preliminary
toxicological evaluation of AVI-7100, a phosphorodiamidate
morpholino oligomer with selectively introduced positive charges
(PMOplus™) targeted to a highly conserved region of Influenza A
virus." The presentation will feature preclinical data evaluating
AVI-7100 for use in treating Influenza A.
Ryszard Kole, Ph.D., Senior Vice President of Discovery Research
at AVI, will present during the oral abstract session, Splicing
Applications, at 8 a.m. PDT on Saturday, Oct. 23. The presentation,
766, is titled "Oligonucleotide-Induced Skipping as Treatment for
Duchenne Muscular Dystrophy: Development of AVI-4658."
Both presentations will be posted on the AVI BioPharma Web site
in the "Our Programs" section after their respective sessions are
completed.
AVI-7100 is AVI's lead therapeutic candidate for influenza virus
infections. The investigational drug candidate employs AVI's
patented PMOplus™ technology that selectively introduces positive
charges to its phosphorodiamidate morpholino oligomer (PMO)
backbone to improve interaction between the drug and its
target.
AVI-4658 is AVI's lead investigational drug candidate in
development as a systemically administered treatment for a
substantial subgroup of patients with Duchenne muscular dystrophy
(DMD), a genetic muscle wasting disease caused by failure to
produce dystrophin.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, AVI has built a pipeline
of potentially transformative therapeutic agents, including one in
the clinical development stage for the treatment of Duchenne
muscular dystrophy. For more information, visit www.avibio.com.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024